title: Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme.
abstract: OBJECTIVE
  Recent studies have shown that prescription rates and doses of recommended drugs for chronic heart failure (CHF) are not optimal in daily practice. The aim of the Impact-Reco programme was to analyse prescription rates of CHF drugs in stable outpatients with CHF related to left ventricular (LV) systolic dysfunction in two similar surveys in France.
  
  
  RESULTS
  The two surveys, which included 1917 and 1974 patients, were performed between September 2004 to March 2005 and September 2005 to May 2006, respectively. Prescription rates of angiotensin-converting enzyme-inhibitors (ACE-I) remained stable (71 vs. 68%, respectively), whereas the proportion of patients receiving angiotensin receptor blockers (21 vs. 30%, P < 0.0001) and beta-blockers (65 vs. 70% P < 0.0001) increased significantly. Doses of ACE-I and beta-blockers increased significantly between the two surveys. However, the improvement was of lesser magnitude in some subgroups of patients, such as elderly patients or patients with renal failure.
  
  
  CONCLUSIONS
  The Impact-Reco programme found an improvement in prescription rates and in the dosage of neurohumoral antagonists in French outpatients with stable CHF. However, there is still room for improvement, especially regarding the doses of medications and the treatment of some subgroups of patients such as the elderly and patients with renal failure.
authors.affiliation: Pôle de Cardiologie et Maladies Vasculaires, CHRU de Lille, Université de Lille 2, France.
authors.forename: Pascal
authors.initials: P
authors.lastname: de Groote
authors.forename: Richard
authors.initials: R
authors.lastname: Isnard
authors.forename: Pierre
authors.initials: P
authors.lastname: Clerson
authors.forename: Guillaume
authors.initials: G
authors.lastname: Jondeau
authors.forename: Michel
authors.initials: M
authors.lastname: Galinier
authors.forename: Patrick
authors.initials: P
authors.lastname: Assyag
authors.forename: Nacima
authors.initials: N
authors.lastname: Demil
authors.forename: Alain
authors.initials: A
authors.lastname: Ducardonnet
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Thebaut
authors.forename: Michel
authors.initials: M
authors.lastname: Komajda
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002908:Chronic Disease; D015897:Comorbidity; D005602:France; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D019538:Health Care Surveys; D006333:Heart Failure / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D013148:Spironolactone / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D013148:Spironolactone